Amneal Pharmaceuticals vs Organon
AMRX and OGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRX and OGN compare
Amneal Pharmaceuticals is the larger company, worth 1.9 times as much as Organon ($6.8B against $3.7B).
On earnings, Organon is cheaper: it trades at 18.1× trailing earnings, against 50.9× for Amneal Pharmaceuticals.
Amneal Pharmaceuticals grew revenue faster over the last twelve months (8.9% versus −3.2% for Organon).
Amneal Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.2% compared with 3.5% at Organon.
Organon pays a dividend yielding 0.58%; Amneal Pharmaceuticals does not pay one.
Amneal Pharmaceuticals scores higher on the StockData Score (12 against 8 for Organon), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRX | OGN |
|---|---|---|
| Size and price | ||
| Market cap | $6.8B | $3.7B |
| Share price | $21.38 | $13.90 |
| Change, 1 year | 79.7% | 80.3% |
| Change, 5 years | 363% | −55.5% |
| Beta (5Y) | 1.07 | 0.82 |
| Employees | 8,500 | 10K |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 0 | 2 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 5 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 50.9× | 18.1× (better) |
| P/S | 2.1× | 0.6× (better) |
| P/B | 12.9× | 3.1× (better) |
| EV/EBITDA | 20.1× | – |
| P/FCF | 77.4× | 5.4× (better) |
| FCF yield | 1.3% | 18.5% (better) |
| Fair value | $13.10 | $15.38 |
| Margin of safety | −63.2% | 9.6% (better) |
| Growth | ||
| Revenue growth (TTM) | 8.9% (better) | −3.2% |
| Revenue growth, 5Y average | 8.7% (better) | −0.99% |
| Net income growth (TTM) | 2159% (better) | −57.5% |
| EPS growth (TTM) | 2000% (better) | −59.9% |
| EPS growth, 5Y average | −18.5% (better) | −39.0% |
| Profitability | ||
| Gross margin | 40.2% | 53.1% (better) |
| Operating margin | 15.0% | – |
| Net margin | 4.2% (better) | 3.5% |
| FCF margin | 2.8% | 11.1% (better) |
| Return on equity | 63.2% (better) | 20.3% |
| Return on invested capital | 16.3% | – |
| Financial health | ||
| Debt / equity | 5.53 (better) | 7.17 |
| Net debt / EBITDA | 5.81 | – |
| Current ratio | 1.87 | 2.02 (better) |
| Altman Z-score | 1.88 (better) | 1.04 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.58% |
| Payout ratio | – | 9.4% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.58% (better) |
| Ownership | ||
| Held by institutions | 52.7% | 83.3% |
| Held by insiders | 60.7% | 0.47% |
| Insider net buying, 12 months | −$7.7M | −$200K (better) |
| Short interest, % of float | 9.1% | 7.5% |
Go deeper
- AMRX stock overview
- AMRX income statement
- AMRX valuation and score
- OGN stock overview
- OGN income statement
- OGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.